Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/104970
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Effects of vildagliptin and metformin on blood pressure and heart rate responses to small intestinal glucose in type 2 diabetes. |
Author: | Wu, T. Trahair, L. Little, T. Bound, M. Zhang, X. Wu, H. Sun, Z. Horowitz, M. Rayner, C. Jones, K. |
Citation: | Diabetes Care, 2017; 40(5):702-705 |
Publisher: | American Diabetes Association |
Issue Date: | 2017 |
ISSN: | 0149-5992 1935-5548 |
Statement of Responsibility: | Tongzhi Wu, Laurence G. Trahair, Tanya J. Little, Michelle J. Bound, Xiang Zhang, Hang Wu, Zilin Sun, Michael Horowitz, Christopher K. Rayner and Karen L. Jones |
Abstract: | OBJECTIVE: To evaluate effects of vildagliptin and metformin on blood pressure (BP) and heart rate (HR) responses to intraduodenal (ID) glucose in diet-controlled type 2 diabetes. RESEARCH DESIGN AND METHODS: Study A compared vildagliptin (50 mg) and placebo, given 60 min before a 120-min ID glucose infusion at 2 or 4 kcal/min (ID2 or ID4) in 16 patients. Study B compared metformin (850 mg) and placebo, given 30 min before ID2 over 120 min in 9 patients. RESULTS: Systolic (P = 0.002) and diastolic (P < 0.001) BP were lower and HR greater (P = 0.005) after vildagliptin compared with placebo, without interaction between vildagliptin and the glucose infusion rate. In contrast, HR was greater after metformin than placebo (P < 0.001), without any difference in systolic or diastolic BP. CONCLUSIONS: Vildagliptin reduces BP and increases HR, whereas metformin increases HR without affecting BP during ID glucose infusion in type 2 diabetes. These distinct cardiovascular profiles during enteral nutrient exposure may have implications for postprandial hypotension. |
Keywords: | Intestine, Small Humans Diabetes Mellitus, Type 2 Metformin Adamantane Nitriles Pyrrolidines Glucose Hypoglycemic Agents Blood Pressure Heart Rate Postprandial Period Aged Female Male Dipeptidyl-Peptidase IV Inhibitors Vildagliptin |
Rights: | © 2017 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals .org/content/license. |
DOI: | 10.2337/dc16-2391 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/1066815 http://purl.org/au-research/grants/nhmrc/1022706 http://purl.org/au-research/grants/nhmrc/627011 |
Published version: | http://dx.doi.org/10.2337/dc16-2391 |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.